These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21102252)

  • 1. Novel taxanes/epothilones.
    Dy G
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S490-1. PubMed ID: 21102252
    [No Abstract]   [Full Text] [Related]  

  • 2. New anti-tubulin agents.
    Felip E
    Suppl Tumori; 2002; 1(4):S17-8. PubMed ID: 12415808
    [No Abstract]   [Full Text] [Related]  

  • 3. Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance.
    Edelman MJ; Shvartsbeyn M
    Clin Lung Cancer; 2012 May; 13(3):171-80. PubMed ID: 22133291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel cytotoxic agents for non-small cell lung cancer.
    Edelman MJ
    J Thorac Oncol; 2006 Sep; 1(7):752-5. PubMed ID: 17409954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer.
    Edelman MJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S30-4. PubMed ID: 19362944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epothilones in the treatment of cancer.
    Larkin JM; Kaye SB
    Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspectives of epothilones in breast cancer.
    Cardoso F; de Azambuja E; Lago LD
    Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
    Villanueva C; Dufresne A; Pivot X; Viel E
    Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixabepilone and the narrow path to developing new cytotoxic drugs.
    Gianni L
    J Clin Oncol; 2007 Aug; 25(23):3389-91. PubMed ID: 17606970
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixabepilone: new drug. Similar to taxanes, but no better.
    Prescrire Int; 2009 Aug; 18(102):160. PubMed ID: 19743574
    [No Abstract]   [Full Text] [Related]  

  • 12. Epothilones in breast cancer: current status and future directions.
    Atzori F; Fornier M
    Expert Rev Anticancer Ther; 2008 Aug; 8(8):1299-311. PubMed ID: 18699766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
    Alberti C
    Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70.
    Gehrmann M
    Curr Opin Investig Drugs; 2006 Jun; 7(6):574-80. PubMed ID: 16784029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubulin interacting agents: novel taxanes and epothilones.
    Agrawal NR; Ganapathi R; Mekhail T
    Curr Oncol Rep; 2003 Mar; 5(2):89-98. PubMed ID: 12583825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epothilones in the treatment of ovarian cancer.
    Diaz-Padilla I; Oza AM
    Future Oncol; 2011 Apr; 7(4):559-68. PubMed ID: 21463144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
    Cigler T; Vahdat L
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.